Non–small Cell Lung Cancer

Lung and bronchus cancer is the leading cause of cancer-related death in both men and women.1

The 5-year survival rate for

metastatic lung (and bronchus)

cancer is only

5%.1

Non-small cell lung cancer (NSCLC)

NSCLC, the most prevalent type

of lung cancer, accounts for ≈85%

of all newly diagnosed cases.1

Most patients with mNSCLC have an actionable biomarker.2-13

 

Recent advances have enabled identification of several NSCLC molecular subtypes, offering more patients with mNSCLC opportunities for improved clinical outcomes through targeted, precision treatment options.14

In newly diagnosed patients with mNSCLC, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend testing for all actionable biomarkers, including EGFR, ALK, ROS1, BRAF, NTRK, and PD-L1.15

Announcing the Lung Ambition Alliance, a new partnership between the medical, scientific, and advocacy communities with a bold ambition to eliminate lung cancer as a cause of death.

Visit LungAmbitionAlliance.org to learn more and share your thoughts on the current state of lung cancer.

ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer; NCCN, National Comprehensive Cancer Network; NTRK, neurotrophic tyrosine receptor kinase; PD-L1, programmed death-ligand 1; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase.

References: 1. Cancer Facts and Figures 2019. American Cancer Society; 2019. 2. Sholl LM et al. J Thorac Oncol. 2015;10(5):768-777. 3. Korpanty GJ et al. Front Oncol. 2014;4:204. 4. Baumgart M et al. Expert Rev Precis Med Drug Dev. 2016;1(1):25-36. 5. Baik CS et al.Oncologist. 2017;22(7):786-796. 6. Shaw AT et al. N Engl J Med. 2014;371(21):1963-1971. 7. Bergethon K et al. J Clin Oncol. 2012;30(8):863-870. 8. Borghaei H et al. N Engl J Med. 2015;373(17):1627-1639. 9. Garon EB et al. N Engl J Med. 2015;372(21):2018-2028. 10. Herbst RS et al. Nature. 2014;515(7528):563-567. 11. Herbst RS et al. Lancet. 2016;387(10027):1540-1550. 12. Fehrenbacher L et al; POPLAR Study Group. Lancet. 2016;387(10030):1837-1846. 13. Vaishnavi A et al. Nat Med. 2013;19(11):1469-1472. 14. Li T et al. J Clin Oncol. 2013;31(8):1039-1049. 15. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non–Small Cell Lung Cancer V4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 29, 2019. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go online to NCCN.org.